Given the functional interaction of PALB2 with BRCA1 and BRCA2, and the phenotypic similarities of the associated cancers presented within and by others,8 it is likely these agents will also be of utility in the treatment of PALB2 deficient cancers. The gene discussed is BRCA2; the disease is cancer.